title: Perspective for prophylaxis and treatment of cervical cancer: an immunological approach.
abstract: As the second most common cause of cancer-related death in women, human papilloma virus (HPV) vaccines have been a major step in decreasing the morbidity and mortality associated with cervical cancer. An estimated 490,000 women are diagnosed with cervical cancer each year. Increasing knowledge of the HPV role in the etiology of cervical cancer has led to the development and introduction of HPV-based vaccines for active immunotherapy of cervical cancer. Immunotherapies directed at preventing HPV-persistent infections. These vaccines are already accessible for prophylaxis and in the near future, they will be available for the treatment of preexisting HPV-related neoplastic lesions.
authors.affiliation: Division of Hematology & Oncology, Texas Tech University Health Sciences Center and Southwest Cancer Treatment and Research Center, Lubbock, Texas 79430, USA.
authors.forename: Marjorie
authors.initials: M
authors.lastname: Jenkins
authors.forename: Maurizio
authors.initials: M
authors.lastname: Chiriva-Internati
authors.forename: Leonardo
authors.initials: L
authors.lastname: Mirandola
authors.forename: Catherine
authors.initials: C
authors.lastname: Tonroy
authors.forename: Sean S
authors.initials: SS
authors.lastname: Tedjarati
authors.forename: Nicole
authors.initials: N
authors.lastname: Davis
authors.forename: Nicholas
authors.initials: N
authors.lastname: D'Cunha
authors.forename: Lukman
authors.initials: L
authors.lastname: Tijani
authors.forename: Fred
authors.initials: F
authors.lastname: Hardwick
authors.forename: Diane
authors.initials: D
authors.lastname: Nguyen
authors.forename: W Martin
authors.initials: WM
authors.lastname: Kast
authors.forename: Everardo
authors.initials: E
authors.lastname: Cobos
mesh_terms: D052685:Alphapapillomavirus / Q000276:immunology*; D000818:Animals; D002277:Carcinoma / Q000517:prevention & control / Q000628:therapy*; D002471:Cell Transformation, Neoplastic; D002472:Cell Transformation, Viral; D005260:Female; D006801:Humans; D016233:Immunotherapy, Active; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D015229:Sexually Transmitted Diseases, Viral / Q000150:complications / Q000517:prevention & control / Q000821:virology; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control / Q000628:therapy*
chemical_list: D053918:Papillomavirus Vaccines